U.S. Markets closed

ESSA Pharma Inc. (EPIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
27.22-0.14 (-0.51%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close27.36
Open27.06
Bid24.50 x 800
Ask29.25 x 1200
Day's Range26.69 - 28.00
52 Week Range5.20 - 36.00
Volume58,475
Avg. Volume234,106
Market Cap1.071B
Beta (5Y Monthly)1.68
PE Ratio (TTM)N/A
EPS (TTM)-0.99
Earnings DateFeb 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ESSA Pharma to Present at the Jefferies Virtual Healthcare Conference
    PR Newswire

    ESSA Pharma to Present at the Jefferies Virtual Healthcare Conference

    ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Dr. David R. Parkinson, Chief Executive Officer of ESSA, will participate in a fireside chat at the upcoming Jefferies Virtual Healthcare Conference. Dr. Parkinson, along with Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will be available for one-on-one meetings. The conference will take place from June 1 – June 4, 2021.

  • EPIX: Combination Trials Upcoming with Astellas, Bayer, and Janssen…
    Zacks Small Cap Research

    EPIX: Combination Trials Upcoming with Astellas, Bayer, and Janssen…

    By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Update on Phase 1 Trial of EPI-7386 ESSA Pharma Inc. (NASDAQ:EPIX) is currently conducting a Phase 1 clinical trial of EPI-7386 in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed on two or more systemic therapies, including at least one second generation anti-androgen

  • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021
    CNW Group

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021

    ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2021. All references to "$" in this release refer to United States dollars, unless otherwise indicated.